Asia Executives On The Move: BMS, Pfizer, Takeda, RDPAC
Rapid changes in China prompt many pharma companies to shuffle strategies and accelerate personal changes. BMS is getting a new country GM, Pfizer Biopharma China GM is departing and Takeda BU head is stepping down.
You may also be interested in...
Prices of direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature.
Some manufacturers willing to offer global-low prices in exchange for reimbursement coverage in the world's second-largest pharma market.
Astellas’s Xtandi gets its latest approval in China, where Merck’s Keytruda is set for another win.